European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live11-14

European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.89% to 1,323.86 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Grifols (GRFS) and petroleum refiner Equinor (EQNR), which rose 6% and 3.9% respectively. They were followed by lender Banco Bilbao Vizcaya Argentaria (BBVA) and biotech firm BioNTech (BNTX), which were up 2.7% and 1.7% respectively.

The decliners from continental Europe were led by biopharmaceutical companies Genfit (GNFT) and Cellectis (CLLS), which fell 9.7% and 4% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and medical device maker EDAP TMS (EDAP), which dropped 2.9% and 2.1% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and insurance provider Prudential (PUK), which increased 7.1% and 2.5% respectively. They were followed by communications company WPP (WPP) and cruise line operator Carnival (CUK), which rose 1.6% and 1.4% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech firm Trinity Biotech (TRIB), which tumbled 13% and 10% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Amarin (AMRN), which lost 4.4% and 3.9% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment